Profile data is unavailable for this security.
About the company
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
- Revenue in USD (TTM)0.00
- Net income in USD-97.21m
- Incorporated2016
- Employees65.00
- LocationEnliven Therapeutics Inc6200 Lookout RoadBOULDER 80301United StatesUSA
- Phone+1 (720) 647-8519
- Fax+1 (302) 655-5049
- Websitehttps://www.enliventherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.55bn | 580.00 | -- | -- | -- | 2.58 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Agios Pharmaceuticals Inc | 44.79m | -401.27m | 1.55bn | 486.00 | -- | 1.21 | -- | 34.59 | -6.96 | -6.96 | 0.7768 | 22.04 | 0.0282 | 0.1959 | 11.00 | 92,162.55 | -25.26 | -10.38 | -26.90 | -11.09 | 87.22 | -- | -895.86 | -768.40 | 13.39 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
| Alvotech SA | 573.35m | 69.50m | 1.56bn | 1.01k | 23.84 | -- | 14.80 | 2.71 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.57bn | 60.00 | -- | 5.60 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Sionna Therapeutics Inc | 0.00 | -70.68m | 1.57bn | 48.00 | -- | 4.87 | -- | -- | -1.61 | -1.61 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -26.35 | -- | -27.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.60bn | 31.00 | -- | 19.83 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.60bn | 74.00 | -- | 9.55 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.60bn | 65.00 | -- | 3.36 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.61bn | 155.00 | -- | 8.33 | -- | 24.19 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| Pharvaris NV | 0.00 | -192.78m | 1.61bn | 108.00 | -- | 4.44 | -- | -- | -3.44 | -3.44 | 0.00 | 5.66 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.62bn | 43.00 | -- | 4.16 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.64bn | 317.00 | -- | 3.01 | -- | 19.53 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.65bn | 263.00 | -- | 5.21 | -- | 12.25 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.40 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
Data as of Feb 06 2026. Currency figures normalised to Enliven Therapeutics Inc's reporting currency: US Dollar USD
50.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 6.94m | 11.69% |
| Commodore Capital LPas of 30 Sep 2025 | 4.69m | 7.91% |
| Fairmount Funds Management LLCas of 30 Sep 2025 | 3.71m | 6.25% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.12m | 5.26% |
| Polar Capital LLPas of 30 Sep 2025 | 3.10m | 5.22% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.45m | 4.13% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 1.78m | 3.00% |
| Blackstone Alternative Asset Management LPas of 30 Sep 2025 | 1.32m | 2.23% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2025 | 1.32m | 2.22% |
| Pictet Asset Management SAas of 31 Dec 2025 | 1.30m | 2.20% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
